Key facts
- Mana.bio’s last known valuation is $30.8M (Oct 2023).
- It has raised $19.5M; the latest was Seed Round in Sep 2025.
- Notable investors include Andreessen Horowitz, Gaingels, NFX, Base4 Capital, LionBird — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Mana.bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Mana.bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mana.bio
Operator of an artificial intelligence-based drug delivery company intended to facilitate lipid nanoparticle development for oligonucleotide therapies. The company uses technology powered by the integration of machine learning and nanotechnology to identify formulations of lipid nanoparticle systems and focus on gene therapy, including DNA and RNA-based therapeutics, and vaccines, enabling the healthcare industry to get a better drug delivery service.
- Sector
- Healthcare
- HQ
- Tel Aviv, Israel
- Founded
- 2021
- Employees
- 20
- Website
- mana.bio/
- Ownership
- Privately Held (backing)
Mana.bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mana.bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mana.bio in its N-PORT filings yet. We sweep new filings monthly.